|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
61,660,000 |
Market
Cap: |
46.94(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.6394 - $5.57 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile AlloVir is a late clinical-stage cell therapy company developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. Co.'s Pipeline includes: Posoloeucel, which is an allogeneic, off-the-shelf virus-specific T cell (VST) therapy candidate targeting adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus that can lead to devastating viral disease in the allogeneic hematopoietic cell transplant population; and ALVR106, which is an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by human metapneumovirus, influenza, parainfluenza virus and respiratory syncytial virus.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
2,930,870 |
2,930,870 |
Total Buy Value |
$0 |
$0 |
$10,990,763 |
$10,990,763 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
49,815 |
194,004 |
265,777 |
1,488,473 |
Total Sell Value |
$38,529 |
$137,285 |
$313,570 |
$9,885,249 |
Total People Sold |
4 |
4 |
4 |
7 |
Total Sell Transactions |
20 |
39 |
62 |
109 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Atillasoy Ercem |
See Remarks |
|
2022-07-21 |
4 |
S |
$5.38 |
$8,245 |
D/D |
(1,533) |
133,467 |
|
-41% |
|
Hallal David |
Director |
|
2022-07-21 |
4 |
AS |
$5.33 |
$22,528 |
D/D |
(4,227) |
2,073,662 |
|
41% |
|
Sinha Vikas |
See Remarks |
|
2022-07-20 |
4 |
S |
$5.21 |
$7,467 |
D/D |
(1,432) |
938,224 |
|
-41% |
|
Van Beek Jeroen B |
Chief Commercial Officer |
|
2022-07-20 |
4 |
S |
$5.21 |
$5,517 |
D/D |
(1,058) |
401,953 |
|
-41% |
|
Atillasoy Ercem |
See Remarks |
|
2022-07-20 |
4 |
S |
$5.21 |
$2,936 |
D/D |
(563) |
135,000 |
|
-41% |
|
Leen Ann M. |
Chief Scientific Officer |
|
2022-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
65,256 |
|
- |
|
Brainard Diana |
Chief Executive Officer |
|
2022-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
48,125 |
542,112 |
|
- |
|
Van Beek Jeroen B |
Chief Commercial Officer |
|
2022-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
403,011 |
|
- |
|
Hagen Brett R |
Chief Accounting Officer |
|
2022-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,500 |
93,578 |
|
- |
|
Atillasoy Ercem |
See Remarks |
|
2022-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
135,563 |
|
- |
|
Sinha Vikas |
See Remarks |
|
2022-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
29,400 |
939,656 |
|
- |
|
Miller Edward |
General Counsel |
|
2022-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
234,930 |
|
- |
|
Van Beek Jeroen B |
Chief Commercial Officer |
|
2022-06-03 |
4 |
S |
$3.63 |
$1,871 |
D/D |
(515) |
389,011 |
|
-144% |
|
Hallal David |
Director |
|
2022-06-03 |
4 |
AS |
$3.67 |
$241,106 |
D/D |
(65,725) |
2,077,889 |
|
144% |
|
Brainard Diana |
Chief Executive Officer |
|
2022-05-18 |
4 |
S |
$4.33 |
$126,257 |
D/D |
(29,135) |
492,165 |
|
-93% |
|
Van Beek Jeroen B |
Chief Commercial Officer |
|
2022-05-17 |
4 |
S |
$4.40 |
$67,167 |
D/D |
(15,262) |
389,526 |
|
-72% |
|
Bornstein Jeffrey S |
Director |
|
2022-04-26 |
4 |
B |
$4.64 |
$23,197 |
D/D |
5,000 |
40,197 |
2.39 |
54% |
|
Atillasoy Ercem |
See Remarks |
|
2022-04-21 |
4 |
S |
$5.86 |
$9,301 |
D/D |
(1,587) |
121,563 |
|
-39% |
|
Hallal David |
Director |
|
2022-04-21 |
4 |
AS |
$5.87 |
$24,812 |
D/D |
(4,227) |
2,143,614 |
|
39% |
|
Sinha Vikas |
See Remarks |
|
2022-04-20 |
4 |
S |
$6.68 |
$7,767 |
D/D |
(1,162) |
906,633 |
|
-0% |
|
Atillasoy Ercem |
See Remarks |
|
2022-04-20 |
4 |
S |
$6.68 |
$3,028 |
D/D |
(453) |
123,150 |
|
-0% |
|
Van Beek Jeroen B |
Chief Commercial Officer |
|
2022-04-20 |
4 |
S |
$6.68 |
$5,695 |
D/D |
(852) |
404,788 |
|
-0% |
|
Hagen Brett R |
Chief Accounting Officer |
|
2022-04-20 |
4 |
S |
$6.68 |
$1,845 |
D/D |
(276) |
80,368 |
|
-0% |
|
Hallal David |
Director |
|
2022-03-11 |
4 |
AS |
$7.37 |
$186,068 |
D/D |
(25,244) |
2,147,841 |
|
-27% |
|
Hallal David |
Director |
|
2022-03-10 |
4 |
AS |
$7.55 |
$305,781 |
D/D |
(40,481) |
2,173,085 |
|
-30% |
|
288 Records found
|
|
Page 6 of 12 |
|
|